Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?

Kyle LaHucik

Senior Reporter

Clene Nanomedicine said its gold nanocrystal-based drug candidate, which failed an ALS trial last year, was better than placebo in a mid-stage study of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Clene claims its PhII MS tri­al, half its in­tend­ed size, cleared the pri­ma­ry goal. But can the biotech af­ford PhI­II?

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?